Eli Lilly's Experimental Obesity Drug Shows Broad Benefits

Eli Lilly announced that its experimental obesity drug, retatrutide, demonstrated broad benefits, including curbing sleep apnea. The company is also making strategic moves in the vaccine market and is projected for significant growth.

Post Share

Sources

Showing 0 of 2 sources

No articles available in your preferred languages.

2 articles available in other languages below.

seeking-alphanob69d ago

Eli Lilly reports broad benefits for experimental obesity drug retatrutide

Read full article →

YahooDanish69d ago

Eli Lilly makes surprising retreat from major market

Read full article →

Coverage Timeline

First report: Yahoo · 6 Jun, 20:37|Full coverage: 2 · 1h|Window: 1h

Left-leaningCenterRight-leaning

Yahoo6 Jun, 20:37First to report

Eli Lilly makes surprising retreat from major market

1h later

seeking-alpha6 Jun, 21:37Latest update

PERSPECTA

PERSPECTA

Eli Lilly's Experimental Obesity Drug Shows Broad Benefits

Sources

Eli Lilly reports broad benefits for experimental obesity drug retatrutide

Eli Lilly makes surprising retreat from major market

Coverage Timeline

Eli Lilly makes surprising retreat from major market

Eli Lilly reports broad benefits for experimental obesity drug retatrutide

Related Stories

Selena Gomez Sued by Investors for Alleged Fraud in Mental Health Startup

Nvidia Discloses $21 Billion Stake in SpaceX and $30 Billion in Intel

Consortium Seals $1.9 Billion Investment in Liverpool FC, Amit Bhatia Named Vice-Chairman

Berkshire Hathaway Increases Stakes in Alphabet, Delta, and Housing Market

PERSPECTA